Cargando…

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota

Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are characterized by the concepts of lipo- and glucotoxicity. NAFLD is characterized by the accumulation of different lipidic species within the hepatocytes. Bile acids (BA), derived from cholesterol, and conjugated and stored i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Hideki, Svegliati Baroni, Gianluca, Marzioni, Marco, Di Nicola, Francesca, Santori, Pierangelo, Maroni, Luca, Abenavoli, Ludovico, Scarpellini, Emidio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320384/ https://www.ncbi.nlm.nih.gov/pubmed/35888771 http://dx.doi.org/10.3390/metabo12070647

Ejemplares similares

Liver Damage and COVID-19: At Least a “Two-Hit” Story in Systematic Review
por: Montori, Michele, et al.
Publicado: (2023)

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Fecal Microbiota Transplantation in NAFLD Treatment
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

From Pre- and Probiotics to Post-Biotics: A Narrative Review †
por: Scarpellini, Emidio, et al.
Publicado: (2021)

Human Genes Involved in the Interaction between Host and Gut Microbiome: Regulation and Pathogenic Mechanisms
por: Boccuto, Luigi, et al.
Publicado: (2023)

Gut Microbiota and Liver Transplantation: Immune Mechanisms behind the Rejection
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

Nutritional Support in Acute Liver Failure
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

Gut Microbiota and Critically Ill Patients: Immunity and Its Modulation via Probiotics and Immunonutrition
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Gut Microbiota and Obesity: A Role for Probiotics
por: Abenavoli, Ludovico, et al.
Publicado: (2019)

Gut Microbiota According to the Metabolome
por: Scarpellini, Emidio, et al.
Publicado: (2023)

Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic
por: Scarpellini, Emidio, et al.
Publicado: (2020)

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study
por: Scarpellini, E., et al.
Publicado: (2022)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
por: Zhang, Limin, et al.
Publicado: (2016)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
por: Tkach, Sergii, et al.
Publicado: (2022)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)
por: Pierre, Joseph F., et al.
Publicado: (2019)

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis
por: Tschuck, Juliane, et al.
Publicado: (2023)

The human gut microbiota and virome: Potential therapeutic implications
por: Scarpellini, Emidio, et al.
Publicado: (2015)

The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma
por: Balducci, Daniele, et al.
Publicado: (2023)

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids
por: Schmidt, Daniel R., et al.
Publicado: (2011)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo
por: Hassan, Haider M., et al.
Publicado: (2022)

Bile Acids Induce Cdx2 Expression Through the Farnesoid X Receptor in Gastric Epithelial Cells
por: Xu, Yingji, et al.
Publicado: (2010)

Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis
por: van Schaik, Fiona D. M., et al.
Publicado: (2012)

Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
por: Kim, Sun-Gi, et al.
Publicado: (2016)

Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor
por: Tveter, Kevin M, et al.
Publicado: (2020)

Psyllium Fiber Protects Against Colitis Via Activation of Bile Acid Sensor Farnesoid X Receptor
por: Bretin, Alexis, et al.
Publicado: (2023)

Gut–Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology
por: Maroni, Luca, et al.
Publicado: (2020)

Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies
por: Giordano, Debora Maria, et al.
Publicado: (2018)

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target
por: Fuchs, Michael
Publicado: (2012)

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
por: Mueller, Michaela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rj22cl87qc026njqrd04ho5q0s